UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8‑K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: July 21, 2017
(Date of earliest event reported)
BIOPHARMX CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| | |
001-37411 | | 59-3843182 |
(Commission File Number) | | (IRS Employer Identification No.) |
1505 Adams Drive, Suite D Menlo Park, California | | 94025 |
(Address of Principal Executive Offices) | | (Zip Code) |
(650) 889-5020
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12) |
☐ | Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b)) |
☐ | Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
On July 21, 2017, BioPharmX Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company will sell to the Purchasers an aggregate of 5,500,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) at a price of $0.36 per share (the “Offering”). The closing of the Offering is expected to occur on or about July 24, 2017, subject to the satisfaction of certain customary closing conditions.
The net proceeds to the Company from the transactions, after deducting the Company’s estimated offering expenses, are expected to be approximately $1.9 million. The Company intends to use the net proceeds to advance the Company’s dermatology focused drug delivery and clinical programs, including advancing the Company’s lead product BPX-01, and for working capital and other general corporate purposes.
The Shares were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-209026), which was filed with the Securities and Exchange Commission (the “SEC”) on January 19, 2016 and subsequently declared effective on February 4, 2016, and a related prospectus. A prospectus supplement relating to the Offering will be filed with the SEC.
The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is filed with this report only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.
The form of the Purchase Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K. The foregoing summary of the terms of the Purchase Agreement is subject to, and qualified in its entirety by, such document, which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)
| |
| |
Exhibit No. | Description |
| |
5.1 | Opinion of Fenwick & West LLP |
| |
10.1 | Form of Securities Purchase Agreement |
| |
23.1 | Consent of Fenwick & West LLP (contained in Exhibit 5.1) |
| |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| BIOPHARMX CORPORATION |
| |
Date: July 21, 2017 | By: | /s/ Greg Kitchener |
| | Name: | Greg Kitchener |
| | Title: | Chief Financial Officer |
EXHIBIT INDEX
| |
Exhibit No. | Description |
| |
5.1 | Opinion of Fenwick & West LLP |
| |
10.1 | Form of Securities Purchase Agreement |
| |
23.1 | Consent of Fenwick & West LLP (contained in Exhibit 5.1) |
| |
